Ludwig Institute for Cancer Research Limited

Beatrice Gaugler

Thierry R Boon-Falleur

Benoit Van Den Eynde

Pierre Van Der Bruggen

Etienne De Plaen

Catia Traversari

Christophe Lurguin

Christophe Lurquin

Bernard Lethe

Pedro Romero

Etienne DePlaen

Christoph Lurquin

Francis Basseur

Nathalie Brouwenstijn

Peter Schrier

The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules

The invention involves nonapeptides bound by HLA molecules such as HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Isolated nonapeptides presented by HLA molecules, and uses thereof

The invention describes the RAGE tumor rejection antigen precursor family, including nucleic acids encoding such tumor rejection antigen precursors, tumor rejection antigen peptides or precursors thereof and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a RAGE tumor rejection antigen precursor.

Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and

The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by HLA molecules HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Isolated cytolytic T cells specific for complexes of MAGE related

A method for determining head and neck squamous cell carcinomas, bladder tumors and prostate carcinomas is described. The method involves assaying for expression of the gene coding for tumor rejection antigen precursor MAGE-3, or its expression product. Various assays, and kits useful for these assays, are described.

Method for determining head and neck squamous cell carcinomas, prostate

The invention relates to isolated nucleic acid molecules which encode nonapeptides derived from MAGE tumor rejection antigen precursors. The nonapeptides form complexes with human leukocyte antigens presented on the surfaces of cells, and lead to lysis of these cells by cytolytic T lymphocytes. Thus, they are useful in diagnostic methods. Also a part of the invention are vectors which are designed to encode the nonapeptides as well as cell lines which have been transformed or transfected with the isolated nucleic acid molecules of the invention, or vectors including these molecules.

Growing community of inventors

Brussels, Belgium

Beatrice Gaugler